% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • snow_tracks snow_tracks Nov 17, 2012 7:19 PM Flag

    Roche's cancer drug Avastin failed data point

    ZURICH (Reuters) - Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the company said on Saturday.

    The Phase III AVAglio study presented at the Society for Neuro-Oncology congress in Washington on Saturday showed Avastin, combined with radiation and chemotherapy, reduced the risk of cancer worsening or death, the Basel-based drugmaker said in a news release.

    But the drug did not reach statistical significance in overall survival, a key data point. Further data are expected next year, Roche said.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.93-0.08(-3.98%)12:16 PMEDT